Skip to content

Different concentration solutions for the oxytocin drip to treat slow progress during the labour of obese first-time mothers

Different oxytocin concentration for labour dystocia in obese nulliparas: a double-blind randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN10741667
Enrollment
126
Registered
2025-01-07
Start date
2025-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Labour dystocia in obese nulliparas Pregnancy and Childbirth

Interventions

Recruitment Potentially eligible nulliparas in spontaneous labour and labour dystocia with the decision made to augment labour with oxytocin will be further screened for eligibility for trial particip

Sponsors

University Malaya Medical Centre
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. BMI =27.5 kg/m2 2. Spontaneous labour (contraction >2:10 minutes and cervical dilatation =3cm) 3. Inadequate progress as clinically determined 4. Nulliparous (no previous pregnancy =22 weeks) 5. Term =37 weeks 6. Age 18-45 years old 7. Membranes ruptured (including prelabour rupture of membranes) 8. Singleton pregnancy 9. Cephalic presentation 10. Reassuring fetal heart rate tracing at initiation of oxytocin infusion

Exclusion criteria

Exclusion criteria: 1. Induced labour (prior Foley, prostaglandin or oxytocin for labour induction) 2. Previous uterine scar (caesarean/myomectomy/perforation) 3. Known major fetal anomaly 4. Fetal weight clinically estimated to be =2 kg and =4 kg and confirmed by ultrasound

Design outcomes

Primary

MeasureTime frame
The time interval from the start of oxytocin augmentation to the birth measured using data collected from the patient's electronic medical record at one timepoint

Secondary

MeasureTime frame
Performance and safety secondary outcomes partly derived from the core outcome set for reporting trials on induction of labour (CROWN) Maternal secondary outcomes: 1. Maximum oxytocin infusion rate used measured using data collected from the patient's electronic medical record after delivery 2. Duration of oxytocin infusion measured using data collected from the patient's electronic medical record after delivery 3. Total volume infused measured using data collected from the infusion pump record or patient's electronic medical record after delivery 4. Cardiotocographic abnormality through the first stage of labour as defined below measured using data from a blinded assessor after delivery, as follows: 4.1. Tachysystole (contractions =6 in 10 minutes) 4.2. Hypertonus (sustained contraction =2 minutes) 4.3 Hyperstimulation syndrome (tachysystole and/or hypertonus with concurrent fetal deceleration [defined as a decrease in fetal heart rate of =15 bpm from baseline for =15 seconds]) 5. Number of doses of tocolytic given if any measured using data collected from the patient's electronic medical record after delivery 6. Mode of delivery measured using data collected from the patient's electronic medical record after delivery, as follows: 6.1. Spontaneous 6.2. Vacuum 6.3. Forceps 6.4. Caesarean section 7. Indication for the Caesarean section measured using data collected from the patient's electronic medical record after delivery 8. Indication for instrumental vaginal delivery measured using data collected from the patient's electronic medical record after delivery 9. Maternal satisfaction with the birth process measured using the 11-point 0-10 numerical rating scale [NRS] after delivery 10. Blood loss during delivery measured using data collected from the patient's electronic medical record after delivery 11. Third- or fourth-degree tear measured using data collected from the patient's electronic medical record after delivery 12. Maternal fever measured using data coll

Countries

Malaysia

Contacts

Public ContactThai Ying Wing
thaiying@ummc.edu.my+60169459213

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jul 3, 2026